<DOC>
	<DOCNO>NCT02225288</DOCNO>
	<brief_summary>This single-center , 4-group , open-label study Japanese healthy elderly male . A total 48 subject randomize one four group ( A D , 12 subjects/group ) administer one E2022 tape designate site .</brief_summary>
	<brief_title>A Study E2022 Tape Formulation ( Overlay-integrated E2022 18 mg Tape Formulation ) Different Application Sites Intervals Japanese Healthy Elderly Males</brief_title>
	<detailed_description>This study consist Screening , Treatment Period , Follow-up . The Treatment Period subdivide three period ( Periods 1 3 ) . Screening start within 4 week start Treatment Period 1 . In Treatment Periods 1 2 , one E2022 tape apply designate site . The Treatment Period 2 application must least 17-day interval end Treatment Period 1 application . In Treatment Period 3 , E2022 tape apply back site ( contralateral first apply site Treatment Periods 1 2 ) least 17 day end Treatment Period 2 ( remove ) . A new E2022 tape apply site specify interval end previous application ( remove ) group . Follow-up start least 17-day interval end re-application Treatment Period 3 ( remove ) .</detailed_description>
	<criteria>Inclusion Criteria 1 . Male nonsmoker ( smoke least 4 week Period 1 ) age 65 year old inform consent 2 . BMI screen 18.5 kg/m2 28.0 kg/m2 3 . Written inform consent 4 . Given full explanation study willing able comply protocol requirement Exclusion Criteria 1 . Have current past history disorder require medical treatment within 8 week first application infection within 4 week first application 2 . Have disorder within 4 week first application affect evaluation study drug psychiatric , gastrointestinal , hepatic , renal , respiratory , endocrinological , hematological , neurological cardiovascular system , congenital metabolic abnormality 3 . Have history gastrointestinal surgery ( e.g. , liver , kidney , digestive tract ) affect pharmacokinetics study drug 4 . Have history treatmentrequiring drug food allergy seasonal allergy screen 5 . Had caffeinecontaining food drink alcohol within 72 hour study drug application Period 1 6 . Had nutritional supplement , herbal preparation ( include oriental medicine ) others ( e.g. , grapefruitcontaining food beverage ) may affect drug metabolize enzyme transporter , within 1 week Period 1 7 . Have use liquid product ( include cosmetic ) study application site ( back , upper limb , chest ) , patch , tape bandage , within 4 week Period 1 8 . Present past clinical sign skin hypersensitivity topical product atopic dermatitis 9 . Excessively hairy shave application site ( back , upper limb , chest ) within 4 week Period 1 10 . Eczema , dermatitis , abnormal pigmentation , injury , scar application site may affect evaluation skin symptom</criteria>
	<gender>Male</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Healthy Subjects</keyword>
	<keyword>Japanese</keyword>
	<keyword>Males</keyword>
</DOC>